tuneTypical Dose
100-200 mg per day
Natural Compound
Ubiquinol
Ubiquinol (reduced form of Coenzyme Q10)
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
2-4 weeks for serum elevation. Months for clinical cardiovascular endpoints.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Ubiquinol is the reduced form of CoQ10 and may have improved absorption in some people. It is used for mitochondrial energy support, heart function outcomes, and statin-associated symptom protocols.
Like CoQ10, ubiquinol supports electron transport and antioxidant defenses, with some evidence of improved absorption compared with ubiquinone. Studies suggest potential benefits for heart failure symptoms and statin-associated muscle complaints, though effects vary. Minority evidence includes reduced fatigue and improved male fertility biomarkers. Benefits are most likely in older adults or those with low baseline CoQ10 levels.
Essential electron carrier in the mitochondrial electron transport chain. The reduced/active form of CoQ10 with superior bioavailability in older adults.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Supports mitochondrial energy production
- Improves ejection fraction in heart failure
Secondary Outcomes
- Alleviates statin-induced myopathy
- Potent lipid-soluble antioxidant
Safety
Contraindications and Interactions
Contraindications
- Warfarin use without INR monitoring
Side effects
- Mild GI upset
- Insomnia if taken late
Interactions
- Warfarin (reduced efficacy)
- Antihypertensives (additive BP lowering)
- Chemotherapy agents (debated)
Avoid if
- On warfarin without physician supervision
Evidence
Study-level References
ubiquinol-SRC-001Sequential within-subject comparative supplementation study.
Sourceopen_in_newLangsjoen PH, Langsjoen AM. Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone. Clin Pharmacol Drug Dev. 2014;3(1):13-17. doi:10.1002/cpdd.73. PMID:27128225.
Population: Healthy adult volunteers.
Dose protocol: Source-listed
Key findings: Ubiquinol supplementation resulted in significantly higher plasma CoQ10 levels compared to ubiquinone at the same dosage, demonstrating superior bioavailability in an aging population.
Paper content
This 12-person comparative supplementation study found that 200 mg/day ubiquinol produced substantially higher steady-state plasma CoQ10 concentrations than an equivalent dose of ubiquinone using matched softgel excipients. Total CoQ10 rose to 4.3 microg/mL with ubiquinol versus 2.5 microg/mL with ubiquinone, and the CoQ10/cholesterol ratio also improved more strongly with ubiquinol. No side effects were reported. The study is small and not a hard-endpoint clinical trial, but it remains a foundational human bioavailability comparison supporting the preference for ubiquinol when absorption matters.
ubiquinol-SRC-002Randomized, double-blind, placebo-controlled pilot study.
Sourceopen_in_newLeaovitavat R, Palakornkitti P, Thetsana P, Teng-Umnuay P. Effects of Ubiquinol on Oxidized Low-Density Lipoprotein in Prediabetic Patients: A Randomized, Double-Blinded, Placebo-Controlled Study. Biomed Res Int. 2026;2026:8739655. doi:10.1155/bmri/8739655. PMID:41810217.
Population: Prediabetic adults.
Dose protocol: Ubiquinol 100 mg/day for 12 weeks.
Key findings: Significant within-group reduction in plasma oxidized LDL from baseline (P=0.049). Between-group difference not significant in this small pilot.
Notes: Pilot RCT in prediabetic adults. Supports antioxidant mechanism in a metabolically at-risk population.
Paper content
This randomized, double-blind, placebo-controlled pilot study tested ubiquinol 100 mg/day for 12 weeks in 20 prediabetic adults. The ubiquinol group showed a significant within-group reduction in plasma oxidized LDL (oxLDL) from baseline (P=0.049), while the placebo group showed no significant change. The between-group difference did not reach statistical significance, which is expected given the small sample size. This study provides early human evidence that ubiquinol may reduce oxidative modification of LDL in a metabolically at-risk population, consistent with its known lipid-soluble antioxidant mechanism.
ubiquinol-SRC-003Randomized, double-blind, two-period crossover study.
Sourceopen_in_newMei X, Zhu B, Soni K, Kasaraneni K, Panchal N. A Randomized, Double-Blind, Two-Treatment, Two-Period, Crossover Study Investigating the Systemic Bioavailability of a Novel Cocrystal Ubiquinol Formulation Compared with a Ubiquinone Formulation in Healthy Adults. Clin Pharmacol Drug Dev. 2026;15(3):e70042. doi:10.1002/cpdd.70042. PMID:41789786.
Population: Healthy adults.
Dose protocol: Novel cocrystal ubiquinol vs ubiquinone, crossover design.
Key findings: Ubiquinol cocrystal achieved geometric mean ratio of 2.20 for Cmax over ubiquinone, confirming substantially higher bioavailability.
Notes: Modern crossover PK study. Reinforces the bioavailability advantage of ubiquinol with newer formulation technology.
Paper content
This randomized, double-blind crossover study in healthy adults compared a novel cocrystal ubiquinol formulation against standard ubiquinone. The ubiquinol formulation showed substantially higher systemic bioavailability, with a geometric mean ratio of 2.20 for peak plasma concentration (Cmax). This confirms and extends earlier pharmacokinetic evidence that ubiquinol achieves higher plasma CoQ10 levels than ubiquinone, and demonstrates that newer formulation technologies can further enhance the bioavailability advantage. This is directly relevant to the clinical rationale for preferring ubiquinol over ubiquinone in supplementation.